Telmisartan Inhibits TNFα-Induced Leukocyte Adhesion by Blocking ICAM-1 Expression in Astroglial Cells but Not in Endothelial Cells
Authors:
Open Access
- 1 September 2020
- journal article
- research article
- Published by The Korean Society of Applied Pharmacology in Biomolecules & Therapeutics
- Vol. 28 (5) , 423-430
Abstract
Telmisartan is an angiotensin-II receptor blocker and acts as a selective modulator of peroxisome proliferator-activated receptor gamma (PPARγ). Several studies have demonstrated that telmisartan ameliorates depression and memory dysfunction and reduces brain inflammation. We hypothesized that the beneficial effects of telmisartan on brain could be due to modulation of the blood-brain barrier (BBB) function. Here, we examined the effect of telmisartan on tumor necrosis factor alpha (TNF-α)-induced expression of intercellular adhesion molecule 1 (ICAM-1) which plays an important role in leukocyte transcytosis through the BBB. Telmisartan blocked TNF-α-induced ICAM-1 expression and leukocyte adhesion in U87MG human glioma cells but showed no effect on human brain microvascular endothelial cells. In U87MG cells, a PPAR antagonist, GW9662 did not block the effect of telmisartan on ICAM1 expression but rather potentiated. Moreover, GW9662 caused no change in TNF-α-induced ICAM-1 expression, suggesting no implication of PPARγ in the telmisartan effect. Further studies showed that telmisartan blocked TNF-α-induced activation of c-Jun N-terminal kinase (JNK), extracellular signal-regulated kinase 1/2 (ERK1/2), p38, and nuclear factor-kappa B (NF-κB). In contrast, inhibitors of JNK, ERK1/2 and NF-κB but not p38, blocked ICAM-1 expression induced by TNF-α. Thus, our findings suggest that the beneficial effect of telmisartan is likely due to the reduction of astrocytic ICAM1 expression and leukocytes adhesion to astrocytes, and that this response was mediated by the inhibition of JNK/ERK1/2/NF-κB activation and in the PPAR-independent manner. In conclusion, this study enhances our understanding of the mechanism by which telmisartan exerts the beneficial brain function.Keywords
Funding Information
- Dankook University (R201601384)
This publication has 35 references indexed in Scilit:
- Blood-Brain Barrier: From Physiology to Disease and BackPhysiological Reviews, 2019
- Age-associated physiological and pathological changes at the blood–brain barrier: A reviewJournal of Cerebral Blood Flow & Metabolism, 2016
- The IκB kinase complex in NF‐κB regulation and beyondEMBO Reports, 2013
- Angiotensin II AT1 receptor blockers as treatments for inflammatory brain disordersClinical Science, 2012
- Associations of Anti-Hypertensive Treatments with Alzheimer's Disease, Vascular Dementia, and Other DementiasJournal of Alzheimer’s Disease, 2011
- Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysisBMJ, 2010
- Angiotensin type 1 receptor antagonist inhibits lipopolysaccharide‐induced stimulation of rat microglial cells by suppressing nuclear factor κB and activator protein‐1 activationEuropean Journal of Neuroscience, 2008
- Differential effects of NF-κB and p38 MAPK inhibitors and combinations thereof on TNF-α- and IL-1β-induced proinflammatory status of endothelial cells in vitroAmerican Journal of Physiology-Cell Physiology, 2005
- ICAM-1-Induced Expression of Proinflammatory Cytokines in Astrocytes: Involvement of Extracellular Signal-Regulated Kinase and p38 Mitogen-Activated Protein Kinase PathwaysThe Journal of Immunology, 2000
- Adhesion molecule expression and regulation on cells of the central nervous systemJournal of Neuroimmunology, 1999